ThromboGenics Signs Potential $494M Ex-U.S. Ocriplasmin Deal

LONDON – ThromboGenics NV is getting €75 million (US$98.4 million) up front as part of a €375 million-plus-royalties deal with leading eye care specialist Alcon Inc. for the ex-U.S. rights to ocriplasmin, providing the cash ThromboGenics needs to go it alone in commercializing the vitreous macular adhesion (VMA) treatment in the U.S.